Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Immuneering Corporation IMRX

Healthcare Biotechnology
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6... see more

Current News (NDAQ:IMRX)

Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire 10 days ago

Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates

GlobeNewswire November 12, 2025

Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025

GlobeNewswire November 4, 2025

Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025

GlobeNewswire September 26, 2025

Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi

GlobeNewswire September 25, 2025

Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi

GlobeNewswire September 24, 2025

Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP

GlobeNewswire September 24, 2025

Immuneering Appoints Dr. Thomas Schall as Chairman of the Board

GlobeNewswire September 16, 2025

Immuneering to Announce Updated Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on September 25

GlobeNewswire September 10, 2025
View More News ››

Opinion & Analysis (NDAQ:IMRX)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:IMRX)

IMRX....this has lots of potential....$6.42

This post has been removed in accordance with Community Policy Possible breakout And me without a position I am urinated off Been...
Iseneschal - October 28, 2025

Using technical analysis for this stock.

It is signalling a continuing uptrend for shareholders today,so good luck to all of you guys
coolfooldumbguy - September 25, 2025

Using technical analysis for this stock.

It is signalling a continuing uptrend for shareholders this morning and
coolfooldumbguy - June 19, 2025

Buy buddy buy because it's taking off this morning.

Otherwise you guys out there will be missing out on this one today anyway
coolfooldumbguy - June 17, 2025

Sell buddy sell.

This stock is for day trading purposes only.Otherwise you guys will be left holding the bag.Well you guys were warned.
coolfooldumbguy - January 7, 2025

It's looking really good for this stock today.

Still holding onto all of my shares because we are about to be rewarded with this one,so good luck to all shareholders.
coolfooldumbguy - January 7, 2025
View more Bullboard ››

Sranan Gold Corp.

Sranan Gold Corp.

Sranan Gold Corp. develops, acquires, and explores mineral properties in Canada. The company primarily explores gold deposits ...
View More »